Study demonstrates the potential of VelcadeĀ® treatment and haemodialysis for myeloma patients with renal impairment

A study published recently has shown that Velcade treatment combined with high cut-off haemodialysis (HCOD) is a potentially effective strategy in rescuing renal function and improving outcomes in newly diagnosed myeloma patients with severe renal impairment. Published in the American Journal of Hematology, the researchers found that patients (n=21) treated with Velcade and HCOD responded…

Details